Biofrontera (NASDAQ:BFRI – Get Free Report) announced its quarterly earnings results on Friday. The company reported ($0.42) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.31), FiscalAI reports. Biofrontera had a negative net margin of 13.78% and a negative return on equity of 145.81%. The firm had revenue of $9.07 million during the quarter, compared to analyst estimates of $8.50 million.
Here are the key takeaways from Biofrontera’s conference call:
- Positive Sentiment: FDA approval of Ameluz for superficial basal cell carcinoma gives Biofrontera a second U.S. indication and a non-surgical treatment option using lamps already in dermatology offices. The company expects a full commercial launch in the first quarter of 2027.
- Positive Sentiment: U.S. Customs cleared the redesigned RhodoLED XL-C from the ITC exclusion order, and Biofrontera says remediation has reduced the share of Ameluz sales affected by the order from about 25% to 10%. The company expects field remediation to be substantially complete by the end of the second quarter of 2027, though appeals remain pending.
- Positive Sentiment: Third-quarter revenue rose 29.8% year over year to $9.1 million, with Ameluz tube volume up about 23%; gross margin improved to 74.4% from 70.7%. Management cautioned that much of the volume growth reflected orders brought forward ahead of the ITC order taking effect.
- Positive Sentiment: Biofrontera submitted an application to expand Ameluz use to actinic keratosis on the extremities, neck, and trunk, with an FDA decision date of August 5, 2027. The company says approval could extend treatment to larger body areas using its existing lamps and sales force.
- Negative Sentiment: The company reported $3.2 million in cash at quarter-end and disclosed substantial doubt about its ability to continue as a going concern for at least 12 months. Its mitigation plans include revenue growth, a working credit line, a conditional $1 million divestiture milestone, and potential additional capital; management said these plans have not alleviated the doubt, and the company does not currently meet Nasdaq’s minimum stockholders’ equity requirement.
Biofrontera Price Performance
BFRI traded down $0.17 on Friday, hitting $0.75. 566,781 shares of the stock were exchanged, compared to its average volume of 391,145. The company has a debt-to-equity ratio of 0.78, a current ratio of 1.18 and a quick ratio of 1.08. Biofrontera has a 12 month low of $0.55 and a 12 month high of $1.66. The firm has a market capitalization of $11.17 million, a price-to-earnings ratio of -1.67 and a beta of 0.88. The business has a 50-day moving average of $1.04 and a two-hundred day moving average of $1.03.
Analyst Ratings Changes
Several analysts have issued reports on the company. Wall Street Zen lowered Biofrontera from a “buy” rating to a “hold” rating in a research note on Sunday, September 20th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Biofrontera in a research report on Tuesday, October 13th. Finally, Zacks Research raised shares of Biofrontera from a “strong sell” rating to a “hold” rating in a research report on Monday, August 3rd. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold”.
Read Our Latest Stock Report on BFRI
About Biofrontera
Biofrontera Inc. (NASDAQ:BFRI) is a specialty pharmaceutical company focused on developing and commercializing prescription dermatology products, with an emphasis on treatments for precancerous and cancerous skin conditions. The company primarily serves the U.S. dermatology market through a commercial organization that supports physicians and other healthcare providers. Biofrontera’s principal product is Ameluz (aminolevulinic acid hydrochloride) topical gel, a prescription medication used with photodynamic therapy to treat actinic keratoses.
See Also
- Five stocks we like better than Biofrontera
- Nu Holdings Earnings Show a Compounder Priced Like a Brazil Bet
- Game On: The Hidden Value in Take-Two’s Stock
- LightPath Technologies’ Record Backlog Highlights a Bigger Defense Opportunity
- A 10-Stock Strategy That Balances AI Growth With Cash Flow
Receive News & Ratings for Biofrontera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biofrontera and related companies with MarketBeat.com's FREE daily email newsletter.
